scholarly journals Only serum pepsinogen I and pepsinogen I/II ratio are specific and sensitive biomarkers for screening of gastric cancer

2019 ◽  
Vol 10 (1) ◽  
pp. 82-90 ◽  
Author(s):  
Fariborz Mansour-Ghanaei ◽  
Farahnaz Joukar ◽  
Massood Baghaee ◽  
Masood Sepehrimanesh ◽  
Amineh Hojati
Keyword(s):  
Gastric Cancer ◽  
Plasma Levels ◽  
Serum Levels ◽  
Normal Weight ◽  
Control Group ◽  
Case Group ◽  
Serum Pepsinogen ◽  
Lower Plasma ◽  
Pepsinogen I ◽  
Pepsinogen Ii

AbstractPurposeWe aimed to determine optimal cut-off points of plasma levels of ghrelin and serum levels of pepsinogen I, II, and their ratio for screening of gastric cancer (GC).MethodsBlood samples were taken from 41 patients with confirmed gastric cancer along with 82 patients without malignancy. Serum levels of pepsinogen I and II, plus plasma levels of acylated ghrelin were measured using commercial ELISA kits.ResultsThe case group had significant lower plasma levels of ghrelin, pepsinogen I, and pepsinogen I/II ratio in comparison to the control group (P<0.001). In the control group, there was significant higher serum pepsinogen I (P=0.028) and pepsinogen II (P=0.003) and lower pepsinogen I/II ratio (P=0.020) in males versus females; significantly higher serum pepsinogen II (P=0.047) and lower pepsinogen I/II ratio (P=0.030) in overweight compared to normal weight patients; and significantly lower pepsinogen I/II ratio (P=0.030) in smokers versus non-smoker. In the case group, there was only significantly lower pepsinogen I (P=0.006) in males versus females, and significantly lower plasma ghrelin (P=0.017) in overweight compared to normal weight patients. The characteristic curve analysis indicated that pepsinogen I at a cut-off of 70.95 μg/L and pepsinogen I/II ratio at cut-off of 2.99, had good sensitivity and specificity.ConclusionsJust serums levels of pepsinogen I and the ratio of pepsinogen I/II can be used as biomarker to screen GC.

scholarly journals Serum pepsinogen I and pepsinogen II levels and its ratio in patients with gastric cancer: a case control study

2016 ◽  
Vol 4 (1) ◽  
pp. 356
Author(s):  
Amal Abraham ◽  
T. U. Girish ◽  
B. J. Sharathchandra ◽  
Subbarao V. Madhunapantula ◽  
Manish Kumar Yadav ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Developed Countries ◽  
Screening Tools ◽  
P Value ◽  
Serum Pepsinogen ◽  
Pepsinogen I ◽  
Gastric Cancer Patients ◽  
Pepsinogen Ii

Background:Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The incidence of gastric cancer is found to increase in the developing countries like India due to change in the life style like having smoked food containing nitrates, smoking , alcoholism and consumption of large amount of red chillies. The objective of this study was to measure the serum pepsinogen I and pepsinogen II levels and its ratio in gastric cancer patients admitted in JSS hospital and Bharath Cancer Centre during the period October 2012 to October 2014 and to compare with controls.Methods: 80 patients - 40 patients with gastric cancer and 40 patients control were studied. Serum pepsinogen I (PG I) and pepsinogen II (PG II) levels were measured using ELISA.Results:The mean PG I levels for cancer patients and controls were 93.98μg/dl and 82.156μg/dl respectively, the mean PG II levels were 42.67 μg/dl and 18.79 μg/dl respectively. The PG I/II ratio in cancer patients is 2.75 and 5.73 in controls, the ratio was significantly lower in cancer patients (P value significant).Conclusions:The ultimate aim in the management of carcinoma stomach is the early detection of the disease. At present endoscopy and biopsy is the gold standard of diagnosis. Different screening tools are under development for the diagnosis of the disease. Our study evaluates a test which can be recommended as an alternative to the diagnosis of gastric carcinoma at an early stage.

Serum Pepsinogen I, Pepsinogen II, and Gastrin 17 in Relatives of Gastric Cancer Patients: Comparative Study With Type and Severity of Gastritis

2008 ◽  
Vol 6 (2) ◽  
pp. 174-179 ◽  
Author(s):  
Arghavan Haj–sheykholeslami ◽  
Naser Rakhshani ◽  
Aliakbar Amirzargar ◽  
Reza Rafiee ◽  
S. Mehdi Shahidi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Comparative Study ◽  
Cancer Patients ◽  
Serum Pepsinogen ◽  
Pepsinogen I ◽  
Gastric Cancer Patients ◽  
Pepsinogen Ii

scholarly journals Accuracy of screening for gastric cancer using serum pepsinogen concentrations

Gut ◽  
1999 ◽  
Vol 44 (5) ◽  
pp. 693-697 ◽  
Author(s):  
F Kitahara ◽  
K Kobayashi ◽  
T Sato ◽  
Y Kojima ◽  
T Araki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Atrophic Gastritis ◽  
Sensitivity And Specificity ◽  
Endoscopic Diagnosis ◽  
Screening Methods ◽  
Fundic Gland ◽  
Serum Pepsinogen ◽  
Pepsinogen I ◽  
Pepsinogen Ii ◽  
Receiver Operator Characteristics

BACKGROUND/AIMSThe characteristics of pepsinogen screening for gastric cancer were investigated to establish a suitable cut off point for identifying gastric cancer, using endoscopic diagnosis as the yardstick.SUBJECTS/METHODSSerum pepsinogen concentrations were measured in 5113 subjects who were also screened for gastric cancer by endoscopy. The cut off point for pepsinogen was determined using receiver operator characteristics curves.RESULTSThe most suitable cut off point was a pepsinogen I concentration of less than 70 ng/ml and a ratio of pepsinogen I to pepsinogen II of less than 3.0. Using this cut off point, the sensitivity and specificity of pepsinogen screening for gastric cancer were 84.6% and 73.5% respectively. All cases of gastric cancer in patients with severe atrophic gastritis were detected. However, two of four cases of gastric cancer in patients with mild atrophic gastritis were overlooked. In subjects with mild atrophic gastritis, when gastric cancer arises within the fundic gland region, the size of the lesion determines whether it is possible to detect cancer by serum pepsinogen screening.CONCLUSIONPepsinogen screening has many advantages, including its suitability for combination with other screening methods because it is simple and inexpensive.

SERUM PEPSINOGEN I LEVELS IN GASTRIC CANCER

2013 ◽  
pp. 43-49
Author(s):  
Thi Minh Tam Phan ◽  
Thi Thu Huong Hoang ◽  
Anh Tuyen Nguyen ◽  
Thi Phuong Anh Le ◽  
Nguyen Tuong Van Ha
Keyword(s):  
Gastric Cancer ◽  
Predictive Value ◽  
Area Under The Curve ◽  
Control Group ◽  
Serum Pepsinogen ◽  
Pepsinogen I ◽  
Cancer Group ◽  
And Control ◽  
Group Serum ◽  
Gastric Cancer Group

Objective: Identification of serum Pepsinogen I levels in gastric cancer. Materials and Methods: Serum pepsinogen I levels was measured by enzym-linked immunosorbent assay (ELISA) on 32 patients in the gastric cancer group diagnosed by endoscopy and histology and control group of 30 patients with functional dyspepsia on endoscopy Using the cut-off value: PGI ≤ 70 ng/ml for gastric cancer. Results: Median Pepsinogen I levels in gastric cancer group was 41.07 ng / ml (25% quartile: 27.83 ng / ml, 75% quartile: 61.57 ng/ml) was significantly lower in control group: 102.03 ng / ml (25% quartile: 57.63 ng / ml, 75% quartile: 129.32 ng/ml) (p<0.001). The rate of Serum Pepsinogen I (≤ 70 ng/ml) was 78.1% in patients with gastric cancer, was 26.7% in the control group. Serum Pepsinogen I test in cut-off value ≤ 70 ng/ml had a sensitivity of 78.1%, specificity 73.3%, positive predictive value of 75.8% and the predictive value negative of 75.9% (p <0.001). The results of the ROC curve: area under the curve = 0.846,p <0.0001 at the cut-of of Pepsinogen I levels in our study ≤ 50.83 ng/ml with the optimal sensitivity and specificity were 65.6% and 86.7%. Key words: serum Pepsinogen I, gastric cancer

scholarly journals Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer

2020 ◽  
Vol 48 (3) ◽  
pp. 030006052091482
Author(s):  
Yaping Wang ◽  
Zhiyong Zhu ◽  
Zhilan Liu ◽  
Zhen Zhao ◽  
Xiaohong Xue ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Stage ◽  
Diagnostic Value ◽  
Population Based ◽  
Serum Pepsinogen ◽  
Pepsinogen I ◽  
Pepsinogen Ii

scholarly journals Clinical significance of Serum Pepsinogen I/II and gastrin-17 determination in gastric cancer diagnosis and prognosis

2018 ◽  
Vol 16 ◽  
pp. 205873921878129 ◽  
Author(s):  
Huiguang Xue ◽  
Aihua Yang ◽  
Fuguo Liu ◽  
Xueguo Sun ◽  
Xishuang Liu
Keyword(s):  
Gastric Cancer ◽  
Gastric Ulcer ◽  
Control Group ◽  
Serum Pepsinogen ◽  
Gastric Function ◽  
Pepsinogen I ◽  
Diagnosis And Prognosis ◽  
Cancer Group ◽  
Ulcer Group ◽  
Gastric Cancer Group

Currently, the diagnosis of atrophic gastritis and gastric cancer are mainly made by endoscopy and histopathology. Our study aimed to explore the practical value of Serum Pepsinogen I/II and gastrin-17 in gastric cancer diagnosis and prognosis. We collected 60 cases of gastric ulcer from February 2015 to November 2016 as gastric ulcer group, and 40 cases of gastric cancer treated in the same period as gastric cancer group. In 3  years after gastric cancer, 20 patients were served as postoperative gastric cancer group, and 70 healthy subjects as control group. The results showed that serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes were tested by enzyme-linked immunosorbent assay (ELISA). The serum PGI level of gastric ulcer group was higher than control group ( P  <  0.05). The serum G-17 concentrations in gastric ulcer group, gastric cancer group, and postoperative gastric cancer group were all higher than control group ( P  <  0.05). The area under receiver operating characteristic (ROC) curve of PGI screening was 0.905 and the best cutoff point was PGI  <  75  µg/L. Their sensitivity and specificity were 87.2% and 75.1%; the area under ROC curve of PGI/PGII rate screening was 0.761 and the best cutoff point was PGI/PGII  <  4. Their sensitivity and specificity were 88.9% and 62.3%. Multi logistical regression showed that the level of serum PGI, PGI, and G-17 and the odds ratio (OR) level of gastric cancer risk were 2.093, 2.653, and 0.494 ( P  <  0.05). The examination of Serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes can be used in the diagnosis and prognosis of gastric cancer and has a rather high practical value in monitoring recurrence in postoperative gastric cancer patients.

Sign in / Sign up

Export Citation Format

Share Document